LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Faustine X Luo,1,2 Zhaohui Arter,1,2 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA; 2University of California Irvine School of Medicine, Orange, CA, 92868, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence:...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Lung Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/laura-completes-the-osimertinib-treatment-jigsaw-puzzle-of-egfr-nsclc--peer-reviewed-fulltext-article-LCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139346167922688 |
|---|---|
| author | Luo FX Arter Z Ou SI Nagasaka M |
| author_facet | Luo FX Arter Z Ou SI Nagasaka M |
| author_sort | Luo FX |
| collection | DOAJ |
| description | Faustine X Luo,1,2 Zhaohui Arter,1,2 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA; 2University of California Irvine School of Medicine, Orange, CA, 92868, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, University of California Irvine School of Medicine, 101 The City Drive South, Building 200, Room 410, ZOT 4061, Orange, CA, 92868, USA, Tel +1 714-456-5153, Fax +1 714-456-2242, Email nagasakm@hs.uci.eduAbstract: The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, based on the PACIFIC trial (NCT02125461). However, the utility of durvalumab in EGFR-mutated lung cancer patients is questionable based on post-hoc analysis and multi-institutional retrospective analysis. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI) with proven clinical efficacy in NSCLC. Given that durvalumab showed no benefit in unresectable Stage III EGFR-mutated NSCLC, it is exciting that most recently, the LAURA trial has demonstrated promising outcomes with adjuvant osimertinib in unresectable, stage III EGFR-mutated NSCLC after definitive chemoradiotherapy with significant improvement in PFS compared to placebo. Furthermore, the LAURA trial demonstrates that osimertinib has a protective effect against distant metastases and CNS progression in this patient population. Here, we explore the results of the LAURA trial and how it transforms the standard-of-care treatment for patients with unresectable, stage III EGFR-mutated NSCLC moving forward.Keywords: stage III, chemoradiation, consolidation therapy, epidermal growth factor receptor, tyrosine kinase inhibitor |
| format | Article |
| id | doaj-art-b10f883332ef43ab9df2f752a27d10c2 |
| institution | OA Journals |
| issn | 1179-2728 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Lung Cancer: Targets and Therapy |
| spelling | doaj-art-b10f883332ef43ab9df2f752a27d10c22025-08-20T02:30:19ZengDove Medical PressLung Cancer: Targets and Therapy1179-27282025-04-01Volume 165155102408LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)Luo FXArter ZOu SINagasaka MFaustine X Luo,1,2 Zhaohui Arter,1,2 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA; 2University of California Irvine School of Medicine, Orange, CA, 92868, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, University of California Irvine School of Medicine, 101 The City Drive South, Building 200, Room 410, ZOT 4061, Orange, CA, 92868, USA, Tel +1 714-456-5153, Fax +1 714-456-2242, Email nagasakm@hs.uci.eduAbstract: The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, based on the PACIFIC trial (NCT02125461). However, the utility of durvalumab in EGFR-mutated lung cancer patients is questionable based on post-hoc analysis and multi-institutional retrospective analysis. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI) with proven clinical efficacy in NSCLC. Given that durvalumab showed no benefit in unresectable Stage III EGFR-mutated NSCLC, it is exciting that most recently, the LAURA trial has demonstrated promising outcomes with adjuvant osimertinib in unresectable, stage III EGFR-mutated NSCLC after definitive chemoradiotherapy with significant improvement in PFS compared to placebo. Furthermore, the LAURA trial demonstrates that osimertinib has a protective effect against distant metastases and CNS progression in this patient population. Here, we explore the results of the LAURA trial and how it transforms the standard-of-care treatment for patients with unresectable, stage III EGFR-mutated NSCLC moving forward.Keywords: stage III, chemoradiation, consolidation therapy, epidermal growth factor receptor, tyrosine kinase inhibitorhttps://www.dovepress.com/laura-completes-the-osimertinib-treatment-jigsaw-puzzle-of-egfr-nsclc--peer-reviewed-fulltext-article-LCTTstage iiichemoradiationconsolidation therapyepidermal growth factor receptortyrosine kinase inhibitor |
| spellingShingle | Luo FX Arter Z Ou SI Nagasaka M LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) Lung Cancer: Targets and Therapy stage iii chemoradiation consolidation therapy epidermal growth factor receptor tyrosine kinase inhibitor |
| title | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) |
| title_full | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) |
| title_fullStr | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) |
| title_full_unstemmed | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) |
| title_short | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) |
| title_sort | laura completes the osimertinib treatment jigsaw puzzle of egfr nsclc from stage ib to iv adjuvant osimertinib significantly improves pfs and cns progression in unresectable stage iii egfr mutated nsclc compared to placebo laura nct03521154 |
| topic | stage iii chemoradiation consolidation therapy epidermal growth factor receptor tyrosine kinase inhibitor |
| url | https://www.dovepress.com/laura-completes-the-osimertinib-treatment-jigsaw-puzzle-of-egfr-nsclc--peer-reviewed-fulltext-article-LCTT |
| work_keys_str_mv | AT luofx lauracompletestheosimertinibtreatmentjigsawpuzzleofegfrnsclcfromstageibtoivadjuvantosimertinibsignificantlyimprovespfsandcnsprogressioninunresectablestageiiiegfrmutatednsclccomparedtoplacebolauranct03521154 AT arterz lauracompletestheosimertinibtreatmentjigsawpuzzleofegfrnsclcfromstageibtoivadjuvantosimertinibsignificantlyimprovespfsandcnsprogressioninunresectablestageiiiegfrmutatednsclccomparedtoplacebolauranct03521154 AT ousi lauracompletestheosimertinibtreatmentjigsawpuzzleofegfrnsclcfromstageibtoivadjuvantosimertinibsignificantlyimprovespfsandcnsprogressioninunresectablestageiiiegfrmutatednsclccomparedtoplacebolauranct03521154 AT nagasakam lauracompletestheosimertinibtreatmentjigsawpuzzleofegfrnsclcfromstageibtoivadjuvantosimertinibsignificantlyimprovespfsandcnsprogressioninunresectablestageiiiegfrmutatednsclccomparedtoplacebolauranct03521154 |